S
Stefan Faderl
Researcher at University of Texas MD Anderson Cancer Center
Publications - 586
Citations - 36426
Stefan Faderl is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 96, co-authored 577 publications receiving 34155 citations. Previous affiliations of Stefan Faderl include Penn State Milton S. Hershey Medical Center & Hackensack University Medical Center.
Papers
More filters
Journal ArticleDOI
Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia
Hagop M. Kantarjian,Susan O'Brien,Jorge E. Cortes,Sergio Giralt,Mary Beth Rios,Jianqin Shan,Francis J. Giles,Deborah A. Thomas,Stefan Faderl,Marcos de Lima,Guillermo Garcia-Manero,Richard E. Champlin,Ralph B. Arlinghaus,Moshe Talpaz +13 more
TL;DR: It is concluded that imatinib mesylate effectively controlled CML that recurred after allogeneic SCT, but it was associated with side effects including myelosuppression and recurrence of severe GVHD.
Journal ArticleDOI
Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia
Xavier Badoux,Michael J. Keating,Sijin Wen,Bang Ning Lee,Mariela Sivina,James M. Reuben,William G. Wierda,Susan O'Brien,Stefan Faderl,Steven M. Kornblau,Jan A. Burger,Alessandra Ferrajoli +11 more
TL;DR: Lenalidomide therapy was well tolerated and induced durable remissions in this population of elderly, symptomatic patients with CLL, and a reduction in CCL3 and CCL4 plasma levels was noted in responding patients.
Journal ArticleDOI
Open-Label, Randomized Comparison of Itraconazole versus Caspofungin for Prophylaxis in Patients with Hematologic Malignancies
Gloria Mattiuzzi,Gladys Alvarado,Francis J. Giles,Luis Ostrosky-Zeichner,Jorge E. Cortes,Susan O'Brien,Srdan Verstovsek,Stefan Faderl,Xian Zhou,Issam I Raad,B. Nebiyou Bekele,Gerhard J. Leitz,Ivonne Lopez-Roman,Elihu H. Estey +13 more
TL;DR: In conclusion, intravenous itraconazole and caspofungin provided similar protection against invasive fungal infection during induction chemotherapy, and both drugs were well tolerated.
Journal ArticleDOI
Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Guillermo Garcia-Manero,Francesco Paolo Tambaro,Nebiyou B. Bekele,Hui Yang,Farhad Ravandi,Elias Jabbour,Gautam Borthakur,Tapan M. Kadia,Marina Konopleva,Stefan Faderl,Jorge E. Cortes,Mark Brandt,Yumin Hu,Deborah McCue,Willie Newsome,Sherry Pierce,Marcos de Lima,Hagop M. Kantarjian +17 more
TL;DR: The combination of vorinostat with idarubicin and cytarabine is safe and active in AML and levels of NRF2 and CYBB were associated with longer survival.
Journal ArticleDOI
Phase II Study of R115777, a Farnesyl Transferase Inhibitor, in Myelodysplastic Syndrome
Razelle Kurzrock,M. Albitar,Jorge E. Cortes,Elihu H. Estey,Stefan Faderl,Guillermo Garcia-Manero,D. A. Thomas,Francis Giles,Mary Ellen Ryback,Alain Thibault,P. De Porre,Hagop M Kantarjian +11 more
TL;DR: This study suggests that R115777 has modest activity in MDS patients, but that, in this patient population, 4 weeks of daily doses of 600 mg PO bid is not tolerated.